Home › Mantle Cell Lymphoma › North Carolina › Charlotte
Mantle Cell Lymphoma clinical trials in Charlotte, NC
5 studies for Mantle Cell Lymphoma are looking for participants at sites in and around Charlotte (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
RecruitingPhase 1/2
- Research Site, Charlotte
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
RecruitingPhase 3
- Atrium Health Levine Cancer Institute (Lci), Charlotte
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
RecruitingPhase 1/2
- Research Site, Charlotte
- Research Site, Charlotte
A Study of ARC-02 in B-cell NHL
RecruitingPhase 1
- Levine Cancer Institute, Charlotte
BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL
RecruitingPhase 1
- Atrium Health Levine Cancer Institute - Morehead, Charlotte
Mantle Cell Lymphoma trials in other cities
- Houston, TX15 studies
- Baldwin Park, CA15 studies
- Durham, NC13 studies
- Seattle, WA12 studies
- New York City, NY12 studies
- Milwaukee, WI12 studies
- Boston, MA11 studies
- Nashville, TN11 studies
- Columbus, OH11 studies
- Chicago, IL10 studies
- Rochester, MN9 studies
- Portland, OR9 studies
Other studies in Charlotte
- Cancer (all types)27 studies
- Breast Cancer22 studies
- Multiple Myeloma21 studies
- Non-Small Cell Lung Cancer19 studies
- Acute Myeloid Leukemia16 studies
- Obesity16 studies
- Overweight15 studies
- Colorectal Cancer13 studies
- Ovarian Cancer12 studies
- Heart Failure11 studies
- Metastatic Cancer11 studies
- Head and Neck Squamous Cell Carcinoma10 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.